Hansen MS, Wlfel EM, Jeromdesella S
In three nested casecontrol studies from England and Wales, involving 440,089 patients with T2DM and without ASCVD treated with non-insulin glucose-lowering medication, combined SGLT2i and GLP-1RA therapy used for primary prevention was associated with 30% lower odds of MACE (defined as myocardial infarction/acute coronary syndrome, stroke/transient ischemic attack, and/or cardiovascular death) compared with other combination regimens (OR, 0.70
Similarly, a 2023 observational analysis published in medical literature noted that approximately 40% of semaglutide users reported spontaneous reduction or cessation of smoking without intentional cessation efforts
GLP-1s are generally considered safe when used as prescribed
Larabi, for their help with protein expression, purification, crystallization and X-ray diffraction analyses